ArticleJournal of biological engineering2025
FTO-engineered extracellular vesicles from bone marrow mesenchymal stem cells ameliorate Staphylococcus aureus-induced osteomyelitis via m6A-dependent suppression of autophagy and pyroptosis.
Article in Journal of biological engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Regulatory mechanisms and therapeutic potential of N6-methyladenosine modification in retinal diseases (Review).Molecular medicine reports · 2026Review
- Context-dependent roles of the NLRP3 inflammasome in osteomyelitis and strategies for precision modulation.Frontiers in immunology · 2026Review
- Therapeutic Potential of Exosomes in Bone Infection: Mechanisms of Action, Engineering Strategies, and Translational Applications.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundBone marrow mesenchymal stem cells (BM-MSCs) ameliorate various orthopedic diseases through the secretion of extracellular vesicles (EVs). This study investigates the effects of FTO-overexpressing BM-MSCs-derived EVs (FTO-EVs) on osteocyte autophagy and pyroptosis in Staphylococcus aureus-associated osteomyelitis (OM).
methodsThe expression levels of N6-methyladenosine regulators were investigated in bone tissues and serum EVs obtained from patients with OM. Osteoblast MC3T3-E1 and osteocyte MLO-Y4 cells were induced with Staphylococcal Protein A (SpA) to simulate in vitro OM models, and murine OM models were established by bone drilling followed by local injection of Staphylococcus aureus suspension, both of which were treated with EVs.
resultsFat mass and obesity-associated protein (FTO) was downregulated in the bone tissues or serum EVs from OM patients compare to healthy control. Compared with negative control EVs, FTO-EVs significantly increased FTO expression, elevated cell viability, and inhibited cell death, ATG2A/ATG14-mediated autophagy and NLRP3-mediated pyroptosis in SpA-induced MC3T3-E1 and MLO-Y4 cells. Treatment with FTO-EVs significantly ameliorated bone damage in OM model mice, upregulated the expression of pro-survival proteins in bone tissue, while downregulating key markers of autophagy and pyroptosis. Mechanistically, FTO-EVs N6-methyladenosine dependently downregulated the expression of ATG2A, ATG14 and NLRP3 to modulate autophagy and pyroptosis in SpA-induced MC3T3-E1 and MLO-Y4 cells.
conclusionsIn summary, this study confirms the role of BM-MSCs-derived FTO-EVs in inhibiting the progression of Staphylococcus aureus-related OM both in vivo and in vitro, providing promising therapeutic strategies for clinical treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.